Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

著者: Julie R. McMullen, Esther J. H. Boey, Jenny Y. Y. Ooi, John F. Seymour, Michael J. Keating, Constantine S. Tam - Blood 2014 被引用: 401

To the editor: The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib sets a new standard of care for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL)[1][1],[2][2] and mantle cell lymphoma (MCL).[3][3] Ibrutinib is generally well tolerated and largely